Amgen Inc. $AMGN Shares Sold by Intact Investment Management Inc.

Intact Investment Management Inc. cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 31.7% during the fourth quarter, HoldingsChannel reports. The firm owned 15,300 shares of the medical research company’s stock after selling 7,100 shares during the period. Intact Investment Management Inc.’s holdings in Amgen were worth $5,008,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. West Family Investments Inc. lifted its holdings in shares of Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after purchasing an additional 30 shares in the last quarter. Viawealth LLC lifted its holdings in shares of Amgen by 0.4% in the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after purchasing an additional 30 shares in the last quarter. LOM Asset Management Ltd lifted its holdings in shares of Amgen by 1.2% in the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after purchasing an additional 30 shares in the last quarter. Sittner & Nelson LLC lifted its holdings in shares of Amgen by 0.4% in the third quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock valued at $2,053,000 after purchasing an additional 30 shares in the last quarter. Finally, Smith Salley Wealth Management lifted its stake in shares of Amgen by 0.3% during the fourth quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company’s stock valued at $3,530,000 after buying an additional 30 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced an additional $300 million investment to expand and modernize its U.S. manufacturing footprint in Juncos, Puerto Rico — part of nearly $2 billion of U.S. manufacturing investment over the last year; this strengthens capacity, supply resilience and long-term revenue support. AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR
• Neutral Sentiment: Coverage of the Puerto Rico expansion by major outlets (Reuters, Quartz) highlights the same investment news — useful for validation but not new catalyst beyond the company release. Amgen to invest additional $300 million to boost US manufacturing footprint
• Neutral Sentiment: Health-care stocks were softer in afternoon trade, which can amplify selling in large-cap biopharma names like Amgen even when company fundamentals are unchanged. Sector Update: Health Care Stocks Softer in Afternoon Trading
• Neutral Sentiment: A Zacks note flagged increased investor attention to AMGN; this signals higher scrutiny/flow but doesn’t itself imply directional catalyst. Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Guggenheim trimmed its price target on AMGN to $340 from $351 and kept a Neutral rating — a modest cut but enough to pressure sentiment because it lowers upside expectations versus recent levels. Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

Amgen Stock Performance

Shares of AMGN stock opened at $323.85 on Tuesday. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The company has a debt-to-equity ratio of 5.65, a quick ratio of 0.90 and a current ratio of 1.26. The company has a 50 day moving average price of $358.07 and a 200 day moving average price of $341.12. The firm has a market capitalization of $174.78 billion, a price-to-earnings ratio of 22.54, a price-to-earnings-growth ratio of 3.24 and a beta of 0.44.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter last year, the firm posted $4.90 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts anticipate that Amgen Inc. will post 22.28 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is currently 70.15%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. The Goldman Sachs Group upped their price objective on shares of Amgen from $415.00 to $425.00 and gave the company a “buy” rating in a research note on Friday. Mizuho upped their price objective on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Royal Bank Of Canada upped their price objective on shares of Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Argus upped their price objective on shares of Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Finally, Oppenheimer set a $400.00 price objective on shares of Amgen and gave the company an “outperform” rating in a research note on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $357.12.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.